ANTIHYPERLIPIDEMIC DRUGS MARKET ANALYSIS
Global Antihyperlipidemic Drugs Market: Key Developments
In May 2022, Zydus Lifesciences announced the launch of its Bempedoic acid drug in India under the Bemdac brand for the treatment of uncontrolled levels of bad cholesterol.
In November 2021, Pfizer announced top line results from the Phase 2b study of vupanorsen (PF-07285557), an investigational therapy being developed for potential indications in cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG). The study showed that vupanorsen achieved a statistically significant lowering of non- HDL-C, triglycerides, and other lipoproteins related to cardiovascular disease.
In April 2021, the Food and Drug Administration (FDA) approved Praluent (alirocumab) injection for adult patients with homozygous familial hypercholesterolemia (HoFH), a genetic condition that causes severely high cholesterol.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
